What is Enzon Pharma's earnings per share (EPS)?

Enzon Pharma (ENZN) reported diluted earnings per share of $-0.07 for fiscal year 2025. This represents a -600.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Enzon Pharma Financials

ENZN

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Enzon Pharma (ENZN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ENZN FY2025 2026-04-22

Enzon’s filings show a cash-heavy structure being steadily depleted by operating losses and distributions rather than scaled operations.

From FY2023 to FY2025, operating cash flow swung from $1.3M inflow to -$3.0M outflow, which is the cleaner operating signal because reported revenue was absent or tiny across the recent valid periods. With financing outflows still at $1.3M, that burn translated into a cash balance drop of about $4.3M in FY2025 rather than just an accounting loss.

A liquidity-versus-solvency split dominates the balance sheet: cash was $42.6M while current liabilities were only $731K, so near-term obligations look small relative to available funds. But total liabilities still exceeded total assets by about $2.5M, leaving negative equity and showing that abundant cash does not automatically mean a positive residual for shareholders.

Because assets are almost entirely cash and no capital spending is reported, this looks like a low-capital-intensity cash pool rather than an operating system being fed by reinvestment. That is why the reported operating loss of -$5.3M matters more than sales growth here: with no meaningful revenue base, overhead and distributions are the main forces moving the balance sheet.

Financial Health Signals

Financial Profile 28/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Enzon Pharma's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Enzon Pharma has elevated debt relative to equity (D/E of -17.96), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.

Liquidity

100

With a current ratio of 58.57, Enzon Pharma holds $58.57 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Piotroski F-Score Weak

3/9

Enzon Pharma passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.88x

For every $1 of reported earnings, Enzon Pharma generates $0.88 in operating cash flow (-$3.0M OCF vs -$3.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$3.4M

YoY-538.2%

Enzon Pharma reported -$3.4M in net income in fiscal year 2025. This represents a decrease of 538.2% from the prior year.

EPS (Diluted)

$-0.07

YoY-600.0%

Enzon Pharma earned $-0.07 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 600.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$42.6M

YoY-9.1%

5Y CAGR-2.4%

10Y CAGR+13.8%

Enzon Pharma held $42.6M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

74M

YoY+0.0%

5Y CAGR+0.0%

10Y CAGR+5.3%

Enzon Pharma had 74M shares outstanding in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

ENZN Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	$26K	N/A	$26K-96.3%	$701K+1248.1%	$52K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	-$5.3M-300.2%	-$1.3M-27.1%	-$1.0M-1.2%	-$1.0M-120.0%	-$469K+64.1%	-$1.3M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$19K-94.5%	$347K+322.4%	-$156K+22.0%	-$200K-2957.1%	$7K0.0%	$7K
Net Income	-$3.4M-538.2%	$778K-43.3%	$1.4M+838.2%	-$186K+60.3%	-$469K+64.2%	-$1.3M
EPS (Diluted)	$-0.07-600.0%	$-0.01	$0.00+100.0%	$-0.02+33.3%	$-0.030.0%	$-0.03

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	$26K	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	-$1.3M+14.9%	-$1.5M-53.0%	-$1.0M	N/A	-$351K-8.0%	-$325K+0.3%	-$326K
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	$16K+138.1%	-$42K-321.1%	$19K	N/A	$49K+1125.0%	$4K+300.0%	$1K
Net Income	N/A	-$824K+16.8%	-$990K-88.9%	-$524K	N/A	$254K-8.0%	$276K-13.8%	$320K
EPS (Diluted)	N/A	$-0.020.0%	$-0.02-100.0%	$-0.01	N/A	$0.00	$0.00	$0.00

ENZN Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$42.8M-9.2%	$47.2M-1.1%	$47.7M+0.2%	$47.6M-0.3%	$47.8M-1.0%	$48.2M
Current Assets	$42.8M-9.2%	$47.2M-0.4%	$47.3M-0.1%	$47.4M-0.8%	$47.8M-1.0%	$48.2M
Cash & Equivalents	$42.6M-9.1%	$46.9M-0.3%	$47.0M+0.1%	$47.0M-1.4%	$47.6M-1.0%	$48.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$45.3M+2.7%	$44.2M-13.8%	$51.2M+15.9%	$44.2M+3.0%	$42.9M+4.9%	$40.9M
Current Liabilities	$731K-56.4%	$1.7M-2.1%	$1.7M+0.9%	$1.7M+321.6%	$403K-2.2%	$412K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$2.5M-183.9%	$3.0M+185.8%	-$3.5M-202.9%	$3.4M-30.0%	$4.9M-33.9%	$7.4M
Retained Earnings	-$73.3M-4.9%	-$69.9M+1.1%	-$70.7M+1.9%	-$72.0M-0.3%	-$71.9M-0.7%	-$71.4M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$42.8M-2.0%	$43.7M-2.4%	$44.8M-1.6%	$45.5M-3.5%	$47.2M-0.2%	$47.3M+0.6%	$47.0M+0.4%	$46.8M
Current Assets	$42.8M-2.0%	$43.7M-2.4%	$44.7M-1.7%	$45.5M-3.5%	$47.2M+0.4%	$47.0M+0.7%	$46.6M+0.4%	$46.5M
Cash & Equivalents	$42.6M-1.6%	$43.3M-2.3%	$44.3M-1.5%	$45.0M-4.0%	$46.9M+0.5%	$46.6M+0.9%	$46.2M+0.5%	$46.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$45.3M+1.6%	$44.6M+0.6%	$44.3M+1.8%	$43.6M-1.3%	$44.2M-0.8%	$44.5M+1.3%	$44.0M+1.0%	$43.5M
Current Liabilities	$731K+35.4%	$540K-32.8%	$803K+44.9%	$554K-67.0%	$1.7M+283.1%	$438K+6.8%	$410K-21.3%	$521K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$2.5M-173.6%	-$923K-313.7%	$432K-77.9%	$2.0M-35.1%	$3.0M+8.9%	$2.8M-9.1%	$3.0M-7.7%	$3.3M
Retained Earnings	-$73.3M-1.5%	-$72.2M-1.2%	-$71.4M-1.4%	-$70.4M-0.7%	-$69.9M-0.1%	-$69.8M+0.4%	-$70.1M+0.4%	-$70.3M

ENZN Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$3.0M-368.3%	$1.1M-14.0%	$1.3M+298.0%	-$659K-31.5%	-$501K-31.8%	-$380K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	-$1.3M0.0%	-$1.3M0.0%	-$1.3M	N/A	$0-100.0%	$43.1M
Dividends Paid	$1.3M0.0%	$1.3M0.0%	$1.3M	N/A	$0	$0
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$682K+34.3%	-$1.0M-54.5%	-$672K-8.7%	-$618K-373.5%	$226K-44.1%	$404K+67.6%	$241K-4.0%	$251K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$0	$0	$0+100.0%	-$1.3M	$0	$0	$0+100.0%	-$1.3M
Dividends Paid	$0	$0	$0-100.0%	$1.3M	$0	$0	$0-100.0%	$1.3M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ENZN Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	-5103.9%	N/A	-3969.2%-3902.3pp	-66.9%+2442.7pp	-2509.6%
Net Margin	N/A	2992.3%	N/A	-715.4%-648.5pp	-66.9%+2454.3pp	-2521.2%
Return on Equity	N/A	25.9%	N/A	-5.5%+4.2pp	-9.6%+8.2pp	-17.8%
Return on Assets	-8.0%-9.6pp	1.7%-1.2pp	2.9%+3.3pp	-0.4%+0.6pp	-1.0%+1.7pp	-2.7%
Current Ratio	58.57+30.5	28.10+0.5	27.62-0.3	27.89-90.6	118.50+1.4	117.07
Debt-to-Equity	-17.96-32.6	14.68+29.3	-14.61-27.6	12.97+4.2	8.81+3.3	5.55
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	-1250.0%	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	1061.5%	N/A
Return on Equity	N/A	N/A	-229.2%-202.3pp	-26.8%	N/A	9.2%+0.1pp	9.1%-0.6pp	9.7%
Return on Assets	N/A	-1.9%+0.3pp	-2.2%-1.1pp	-1.1%	N/A	0.5%-0.0pp	0.6%-0.1pp	0.7%
Current Ratio	58.57-22.3	80.86+25.2	55.71-26.5	82.17+54.1	28.10-79.1	107.24-6.5	113.75+24.6	89.19
Debt-to-Equity	-17.96+30.4	-48.34-151.0	102.66+80.3	22.31+7.6	14.68-1.4	16.12+1.7	14.46+1.2	13.22
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$2.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Sigyn Therapeutics Inc SIGY

$58K

Biophytis Sa BPTSY

$4.6M

Vaxxinity, Inc. VAXX

$13.9M

Glow Lifetech GLWLF

$7.3M

Quantum Genomics QNNTF

$7.0M

Frequently Asked Questions

Is Enzon Pharma profitable?

No, Enzon Pharma (ENZN) reported a net income of -$3.4M in fiscal year 2025.

What is Enzon Pharma's operating cash flow?

Enzon Pharma (ENZN) generated -$3.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Enzon Pharma's total assets?

Enzon Pharma (ENZN) had $42.8M in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does Enzon Pharma have outstanding?

Enzon Pharma (ENZN) had 74M shares outstanding as of fiscal year 2025.

What is Enzon Pharma's current ratio?

Enzon Pharma (ENZN) had a current ratio of 58.57 as of fiscal year 2025, which is generally considered healthy.

What is Enzon Pharma's debt-to-equity ratio?

Enzon Pharma (ENZN) had a debt-to-equity ratio of -17.96 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Enzon Pharma's return on assets (ROA)?

Enzon Pharma (ENZN) had a return on assets of -8.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Enzon Pharma's cash runway?

Based on fiscal year 2025 data, Enzon Pharma (ENZN) had $42.6M in cash against an annual operating cash burn of $3.0M. This gives an estimated cash runway of approximately 170 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Enzon Pharma's debt-to-equity ratio negative or unusual?

Enzon Pharma (ENZN) has negative shareholder equity of -$2.5M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Enzon Pharma's Piotroski F-Score?

Enzon Pharma (ENZN) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Enzon Pharma's earnings high quality?

Enzon Pharma (ENZN) has an earnings quality ratio of 0.88x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Enzon Pharma?

Enzon Pharma (ENZN) scores 28 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.